Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Simple Linctus BP

Active Ingredient:
citric acid monohydrate
Thornton & Ross Ltd See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 09 Sep 2020
1. Name of the medicinal product

Simple Linctus

2. Qualitative and quantitative composition

Citric Acid Monohydrate BP 125mg per 5ml.

Excipients with known effects

Sucrose 4g per 5ml.

For the full list of excipients, see section 6.1

3. Pharmaceutical form


4. Clinical particulars
4.1 Therapeutic indications

For relief of the symptoms of coughs.

4.2 Posology and method of administration


Recommended Doses

Adults, the elderly and children over 12 years: One 5ml spoonful, repeated up to four times per day.

Children under 12 years: Not recommended.

4.3 Contraindications

None Known.

4.4 Special warnings and precautions for use

Keep out of the reach of children.

Not suitable for children under 12 years.

This product contains 4g of sucrose per dose. To be taken into account in people with diabetes mellitus. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

This medicine contains less than 1mmol sodium (23 mg) per 5ml dose, that is to say essentially 'sodium-free'. This medicine contains 2.5mg sodium benzoate per 5ml dose.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Pregnancy and lactation

No adverse effects are known for the product, however, as with all medicines use should be avoided during pregnancy unless recommended by a doctor.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

Tabulated list of adverse reaction(s)

Adverse reactions frequency are defined using the following convention:

Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).

System organ class (MedDRA)


Adverse event

Immune System Disorders

Not known


Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Overdose with this preparation is unlikely to occur due to the low concentrations of the ingredients, however, in the event, treatment should be symptomatic.

5. Pharmacological properties
5.1 Pharmacodynamic properties

None stated.

5.2 Pharmacokinetic properties

None stated.

5.3 Preclinical safety data


6. Pharmaceutical particulars
6.1 List of excipients

Anise flavour (contains propylene glycol)

Sodium benzoate (E211)

Glycerol (E422)

Purified water

Syrup (sucrose)

6.2 Incompatibilities


6.3 Shelf life

36 months unopened. Discard 2 months after first opening.

6.4 Special precautions for storage

Store below 25° C.

6.5 Nature and contents of container


Amber glass bottle with plastic cap and liner or white 28mm cap with tamper evident band and EPE Saranex liner

6.6 Special precautions for disposal and other handling


7. Marketing authorisation holder

L.C.M. Ltd

Linthwaite Laboratories



8. Marketing authorisation number(s)

PL 12965/0032

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text


Thornton & Ross Ltd
Company image
Linthwaite, Huddersfield, West Yorks, HD7 5QH
Medical Information Direct Line
+44 (0) 1484 848164
Medical Information e-mail
[email protected]
Customer Care direct line
+44(0)1484 848200